Amygdala connectivity predicts ketamine treatment response among patients with anxious depression

Amygdala connectivity predicts ketamine treatment response among patients with anxious depression

A brain region known as the amygdala could play a key role in predicting symptom improvement following ketamine therapy in patients with treatment-resistant anxious depression, according to new research published in the Journal of Affective Disorders. “Since the antidepressant effects of ketamine in patients with anxious depression remain unclear, it is necessary to investigate the potential biomarkers predicting the antidepressant efficacy of ketamine in patients with anxious depression,” said study author Bin Zhang of the Affiliated Brain Hospital of Guangzhou …